Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H2 2018’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease)

– The report reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Coronary Artery Disease (CAD) (Ischemic Heart Disease) therapeutics and enlists all their major and minor projects

– The report assesses Coronary Artery Disease (CAD) (Ischemic Heart Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ascendia Pharmaceuticals LLC

AstraZeneca Plc

Athera Biotechnologies AB

Bayer AG

Biscayne Pharmaceuticals Inc

Capricor Therapeutics Inc

CardioVascular BioTherapeutics Inc

CSL Ltd

DalCor Pharmaceuticals Inc

Gilead Sciences Inc

Hemostemix Inc

Human Stem Cells Institute

Idorsia Pharmaceutical Ltd

LipimetiX Development Inc

Livzon Pharmaceutical Group Inc

Lonestar Heart Inc

MedImmune LLC

Merck & Co Inc

Nuo Therapeutics Inc

Orion Corporation

Proteon Therapeutics Inc

Resverlogix Corp

Reven Pharmaceuticals Inc

The Medicines Company

Verseon Corp

VESSL Therapeutics Ltd

ViroMed Co Ltd

XyloCor Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 6

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Development 7

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Assessment 17

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Companies Involved in Therapeutics Development 25

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Profiles 38

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Dormant Projects 163

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Discontinued Products 169

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Product Development Milestones 172

Appendix 187

List of Tables

List of Tables

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Ascendia Pharmaceuticals LLC, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by AstraZeneca Plc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Athera Biotechnologies AB, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Bayer AG, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Biscayne Pharmaceuticals Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Capricor Therapeutics Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by CardioVascular BioTherapeutics Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by CSL Ltd, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by DalCor Pharmaceuticals Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Gilead Sciences Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Hemostemix Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Human Stem Cells Institute, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Idorsia Pharmaceutical Ltd, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by LipimetiX Development Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Livzon Pharmaceutical Group Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Lonestar Heart Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by MedImmune LLC, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Merck & Co Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Nuo Therapeutics Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Orion Corporation, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Proteon Therapeutics Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Resverlogix Corp, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Reven Pharmaceuticals Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by The Medicines Company, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by Verseon Corp, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by VESSL Therapeutics Ltd, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by ViroMed Co Ltd, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline by XyloCor Therapeutics Inc, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Dormant Projects, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Dormant Projects, H2 2018 (Contd..1), H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Dormant Projects, H2 2018 (Contd..2), H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Dormant Projects, H2 2018 (Contd..3), H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Discontinued Products, H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Discontinued Products, H2 2018 (Contd..1), H2 2018

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Discontinued Products, H2 2018 (Contd..2), H2 2018

List of Figures

List of Figures

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports